GWM
GTHX

Geneos Wealth Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Geneos Wealth Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-300
Closed -$6K – 2920
2021
Q2 		$6K Hold
300
– – ﹤0.01% 2418
2021
Q1 		$6K Hold
300
– – ﹤0.01% 2625
2020
Q4 		$7K Buy
+300
New +$4.48K ﹤0.01% 2388

Other funds holding GTHX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geneos Wealth Management's GTHX Position: Q3 2021 in Review

Geneos Wealth Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2021, closing a stake of 300 shares — an estimated $6K sold.

Geneos Wealth Management first reported a position in GTHX in Q4 2020 and held it in 3 quarters. The position peaked at $7K in Q4 2020. 115 funds tracked by Wall St. Rank hold GTHX as of Q3 2021.

  • Geneos Wealth Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Geneos Wealth Management sold 300 G1 Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $6K.
  • Geneos Wealth Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Geneos Wealth Management's G1 Therapeutics, Inc. Common Stock position peaked at $7K in Q4 2020.
  • 115 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Geneos Wealth Management's 13F filing for Q3 2021, filed 9 Nov 2021.